GlassScriptPhysician profile
Michael Ammirati
NPI 1598845349
$8,474.71
in general payments reported to CMS, 2019-2025
28 companies · $800 in 2025
The $800 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $931 · 2020: $1,130 · 2021: $1,413 · 2022: $1,288 · 2023: $1,519 · 2024: $1,396 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,714.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,813.32 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $2,204.21 | 2019-2025 | Linzess, Skyrizi, Creon |
| Madrigal Pharmaceuticals | $472.59 | 2024-2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $458.40 | 2019-2022 | |
| Redhill Biopharma INC. | $317.42 | 2020-2024 | Talicia, Movantik, Aemcolo |
| Merck Sharp & Dohme LLC | $269.49 | 2020-2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $252.33 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $233.19 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $228.49 | 2020-2023 | Injectafer |
| Ironwood Pharmaceuticals, INC | $156.83 | 2020-2024 | Linzess |
| Novo Nordisk INC | $143.17 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $134.64 | 2023 | Zeposia |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Allergan, INC. | $115.57 | 2019-2020 | |
| Janssen Biotech, INC. | $115.14 | 2022-2024 | Stelara, Tremfya |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $63.21 | 2024 | Ibsrela |
| Amgen INC. | $53.13 | 2023 | Repatha |
| Horizon Therapeutics Plc | $48.22 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $43.65 | 2025 | Dupixent |
| Boston Scientific Corporation | $37.92 | 2019-2022 | |
| Capsovision, INC. | $36.01 | 2024 | Capsocam Plus |
| Braintree Laboratories, INC. | $29.46 | 2019-2022 | |
| Celgene Corporation | $28.89 | 2023 | Zeposia |
| Bayer Healthcare Pharmaceuticals INC. | $21.82 | 2021 | |
| Lilly USA, LLC | $19.38 | 2021 | |
| Medtronic, INC. | $18.63 | 2023 | Gi Genius |
| Intercept Pharmaceuticals, INC. | $18.55 | 2022 | |
| Evoke Pharma, INC. | $16.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ammirati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.